Eman S Ramadan1, Noha Y Salem1, Ibrahim A Emam2, Naglaa A AbdElKader2, Haithem A Farghali2, Marwa S Khattab3. 1. Department of Internal Medicine and Infectious Diseases, Faculty of Veterinary Medicine, Cairo University, Giza, 12211, Egypt. 2. Department of Surgery and Anesthesia, Faculty of Veterinary Medicine, Cairo University, 12211, Giza, Egypt. 3. Department of Pathology, Faculty of Veterinary Medicine, Cairo University, 12211, Giza, Egypt. marwakhattab@cu.edu.eg.
Abstract
BACKGROUND: Canine mammary tumors (CMTs) are one of the most common malignancies in dogs and are associated with significant mortality. Serum tumor markers and non-coding microRNAs have gained widespread popularity in human oncology studies. The present study has two aims, first one is to investigate the miR-21 expression compared with changes in serum tumor markers (CEA and CA15-3) in CMT. The second aim is to detect the immunohistochemistry markers as vimentin, P63, and -SMA in CMT. METHODS: This study enrolled 17 female dogs: 10 with mammary tumors and seven controls without tumors. Blood samples were collected to measure miR-21, CEA, and CA 15-3, and histological samples were prepared for histological grading and immunohistochemistry. RESULTS: CA 15-3 was elevated in all animals, whereas CEA levels showed no change compared with controls. miR-21 was upregulated 12.84-fold in animals with CMT. The most frequently recorded CMT was the mixed type. Myoepithelial cells were identified by P63 immunoreactivity, but not SMA. High expression of miR-21 was observed with positive vimentin immunoreactivity, indicating the mesenchymal origin of the tumor cells. CONCLUSION: The present study showed that miR-21 was elevated to a greater extent than CA 15-3 (12.84-fold vs. threefold). Tumors that was positive for vimentin immunoreactivity was also associated with an elevation in the levels of miR-21, showing that miR-21 is released from mesenchymal cells. These findings support the hypothesis that miR-21 may be a more sensitive, noninvasive indicator for CMT.
BACKGROUND: Canine mammary tumors (CMTs) are one of the most common malignancies in dogs and are associated with significant mortality. Serum tumor markers and non-coding microRNAs have gained widespread popularity in human oncology studies. The present study has two aims, first one is to investigate the miR-21 expression compared with changes in serum tumor markers (CEA and CA15-3) in CMT. The second aim is to detect the immunohistochemistry markers as vimentin, P63, and -SMA in CMT. METHODS: This study enrolled 17 female dogs: 10 with mammary tumors and seven controls without tumors. Blood samples were collected to measure miR-21, CEA, and CA 15-3, and histological samples were prepared for histological grading and immunohistochemistry. RESULTS: CA 15-3 was elevated in all animals, whereas CEA levels showed no change compared with controls. miR-21 was upregulated 12.84-fold in animals with CMT. The most frequently recorded CMT was the mixed type. Myoepithelial cells were identified by P63 immunoreactivity, but not SMA. High expression of miR-21 was observed with positive vimentin immunoreactivity, indicating the mesenchymal origin of the tumor cells. CONCLUSION: The present study showed that miR-21 was elevated to a greater extent than CA 15-3 (12.84-fold vs. threefold). Tumors that was positive for vimentin immunoreactivity was also associated with an elevation in the levels of miR-21, showing that miR-21 is released from mesenchymal cells. These findings support the hypothesis that miR-21 may be a more sensitive, noninvasive indicator for CMT.
Authors: R Michelle Boggs; Zachary M Wright; Mark J Stickney; Weston W Porter; Keith E Murphy Journal: Mamm Genome Date: 2008-07-30 Impact factor: 2.957
Authors: L C Campos; G E Lavalle; A Estrela-Lima; J C Melgaço de Faria; J E Guimarães; Á P Dutra; E Ferreira; L P de Sousa; É M L Rabelo; A F D Vieira da Costa; G D Cassali Journal: J Vet Intern Med Date: 2012-11-01 Impact factor: 3.333
Authors: Ana Canadas; Miguel França; Cristina Pereira; Raquel Vilaça; Hugo Vilhena; Flora Tinoco; Maria João Silva; Jorge Ribeiro; Rui Medeiros; Pedro Oliveira; Patrícia Dias-Pereira; Marta Santos Journal: Vet Pathol Date: 2018-10-31 Impact factor: 2.221
Authors: M G Alexandrakis; F H Passam; K Perisinakis; E Ganotakis; G Margantinis; D S Kyriakou; D Bouros Journal: Respir Med Date: 2002-08 Impact factor: 3.415
Authors: Cherie Blenkiron; Leonard D Goldstein; Natalie P Thorne; Inmaculada Spiteri; Suet-Feung Chin; Mark J Dunning; Nuno L Barbosa-Morais; Andrew E Teschendorff; Andrew R Green; Ian O Ellis; Simon Tavaré; Carlos Caldas; Eric A Miska Journal: Genome Biol Date: 2007 Impact factor: 13.583
Authors: Diana Bautista-Sánchez; Cristian Arriaga-Canon; Abraham Pedroza-Torres; Inti Alberto De La Rosa-Velázquez; Rodrigo González-Barrios; Laura Contreras-Espinosa; Rogelio Montiel-Manríquez; Clementina Castro-Hernández; Verónica Fragoso-Ontiveros; Rosa María Álvarez-Gómez; Luis A Herrera Journal: Mol Ther Nucleic Acids Date: 2020-03-13 Impact factor: 8.886